Diabetic foot ulcers are the primary complication of diabetes treated with hyperbaric oxygen therapy (HBOT). These chronic, slow-healing wounds affect about 15% of people with diabetes at some point in their lives, and when standard wound care fails, breathing pure oxygen in a pressurized chamber can significantly improve healing and reduce the risk of amputation. HBOT is also used for two related diabetic complications: chronic bone infections (osteomyelitis) and severe soft tissue infections, both of which frequently develop from the same underlying foot wounds.
Why Diabetic Foot Ulcers Heal So Poorly
Diabetes damages blood vessels and nerves over time, especially in the feet and lower legs. Reduced blood flow starves tissues of oxygen, and nerve damage means injuries often go unnoticed until they become serious. A small blister or cut can progress into a deep ulcer that reaches muscle, tendon, or bone. The oxygen-starved tissue lacks the resources to mount a normal healing response, and the immune system’s infection-fighting cells can’t function well without adequate oxygen.
This is where HBOT targets the problem directly. By flooding the body with oxygen at pressures two to two and a half times normal atmospheric pressure, the therapy reverses tissue-level oxygen starvation. That oxygen boost stimulates new blood vessel growth, improves the ability of white blood cells to kill bacteria, and enhances collagen production, the protein scaffolding that rebuilt tissue needs. It also reduces swelling around the wound and triggers the bone marrow to release stem cells that contribute to repair.
How Effective HBOT Is for Diabetic Ulcers
Meta-analyses pooling data from controlled clinical trials show meaningful benefits. Patients receiving HBOT alongside standard wound care were about 90% more likely to achieve complete wound healing compared to standard care alone. Healing time shortened by roughly 19 days on average. Perhaps most importantly for patients facing the possibility of losing a limb, HBOT cut the risk of major amputation nearly in half.
These results apply specifically to wounds that haven’t responded to conventional treatment. HBOT isn’t a first-line therapy for a fresh ulcer. It’s reserved for cases where proper wound care, offloading pressure from the foot, infection control, and blood sugar management have already been tried and the wound still isn’t closing.
Who Qualifies for Treatment
Medicare covers HBOT for diabetic lower-extremity wounds when three conditions are met: the patient has type 1 or type 2 diabetes with a wound caused by the disease, the wound is classified as Wagner grade III or higher (meaning it extends at least to tendon, joint capsule, or bone), and the patient has already failed an adequate course of standard wound therapy. Many private insurers follow similar criteria.
The Wagner grading system runs from 0 to 5. Grade III wounds involve deep tissue with possible abscess or bone infection. Grade IV means part of the foot has gangrene. Grade V means gangrene has spread across the entire foot. The requirement for a grade III minimum reflects the reality that milder wounds usually respond to standard care, while deeper wounds are the ones that benefit most from the added oxygen.
What Treatment Looks Like
During each session, you sit or lie in a pressurized chamber and breathe 100% oxygen, typically at 2.0 to 2.5 times normal atmospheric pressure. Sessions last 60 to 120 minutes, with short air breaks every 30 minutes to reduce the risk of oxygen-related side effects. Most protocols call for treatments five or six days per week.
The total number of sessions varies. Clinical studies have used anywhere from 20 to over 100 sessions, but research suggests a minimum of about 30 sessions is needed for the therapy to be clinically effective. A typical course runs 30 to 40 sessions, meaning treatment spans roughly six to eight weeks. Your wound care team monitors progress throughout and may adjust the number of sessions based on how the ulcer responds.
Blood Sugar During Treatment
One practical concern for diabetic patients is the effect of HBOT on blood glucose. A review of over 3,100 treatment sessions in patients with diabetes found that hypoglycemia (blood sugar dropping to 70 mg/dL or below) occurred in only 1.5% of sessions, and symptomatic or severe drops were rare. People with type 1 diabetes had a higher risk, roughly 3.7 times greater than those with type 2. A pre-session blood sugar reading around 150 mg/dL or above was a reliable indicator that hypoglycemia during treatment was unlikely. Most treatment centers check your glucose before each session as a precaution.
Chronic Bone Infection in Diabetic Feet
When a diabetic foot ulcer extends to bone, it can cause osteomyelitis, a stubborn infection that antibiotics alone sometimes can’t clear. If surgical cleaning of the bone and culture-directed antibiotics haven’t resolved the infection after four to six weeks, the condition is classified as chronic refractory osteomyelitis, and HBOT becomes an appropriate addition to the treatment plan.
The oxygen-rich environment created by HBOT enhances the body’s immune response against the bacteria commonly found in bone infections. It also improves the penetration of certain antibiotics into bone tissue, making the drugs more effective. Treatment for osteomyelitis typically involves 40 to 60 sessions at 2.4 atmospheres for 90 minutes each. For diabetic patients with Wagner grade 3 or 4 ulcers complicated by osteomyelitis, this is considered a top-tier clinical intervention.
Necrotizing Soft Tissue Infections
Necrotizing fasciitis, sometimes called “flesh-eating” infection, is a rapidly spreading, life-threatening condition that destroys skin, fat, and muscle. Diabetes is the single most common underlying condition in patients who develop it, because elevated blood sugar and impaired circulation create an environment where aggressive bacterial infections can take hold quickly.
Emergency surgery to remove dead tissue is the primary treatment, but adding HBOT substantially improves survival. A systematic review found that the mortality rate for patients who received HBOT was 10.6%, compared to 25.6% for those treated without it. One individual study reported an even starker difference: 7% mortality with HBOT versus 42% without. The therapy also reduced the rate of complications overall. While necrotizing fasciitis is far less common than chronic foot ulcers, its high fatality rate makes HBOT a potentially lifesaving addition when it’s available.